CommercialPrior AuthHigh impact
Liver Transplantation (CPB 0596, reviewed 2026-03-02)
Aetna·Transplant Surgery, General Surgery, Gastroenterology +2 more·Medical Policy
Effective date
Mar 2, 2026
We identified it
Aug 19, 2026
Summary
Aetna has updated its Liver Transplantation policy (CPB 0596, effective 2026-03-02) establishing medical necessity criteria for liver transplant coverage based on MELD scores, UNOS approval, and institutional selection criteria. The policy specifies covered indications (cholestatic diseases, hepatocellular diseases, malignancies, vascular diseases, metabolic disorders, and miscellaneous conditions), lists absolute contraindications including active substance abuse with exceptions for documented 3-month stability, and designates numerous interventions as experimental/investigational. Billing teams must immediately implement prior authorization requirements and validate claims against the specified covered indications and contraindications.
Action Required
By 2026-03-02: (1) Billing team must implement prior authorization workflows in billing software for all liver transplant CPT codes (47133, 47135, 47140, 47141, 47142, 47143, 47144, 47145) for Aetna Commercial plans. (2) Develop verification checklist requiring claims processors to confirm: MELD score >10 OR UNOS Regional Review Board approval OR institutional selection criteria documentation before claim submission. (3) Flag absolute contraindications (active sepsis outside biliary tract, inability to adhere to transplant regimen, active substance abuse without 3-month documented stability, significant organ system failure other than kidney/liver/small bowel) for denial review. (4) Update encounter form templates to require transplanting institution name and selection criteria documentation for patients <12 years old. (5) Configure system to route experimental procedure codes (basiliximab, bioartificial liver, biomarkers, ectopic/auxiliary transplant, everolimus, hepatocyte transplantation, machine perfusion variants, and others listed in policy) to medical necessity review before processing. (6) Providers must submit substance abuse stability documentation (within 4 weeks from treating addiction professional or psychiatrist) to override contraindication for applicable cases. Failure to obtain prior authorization or validate coverage criteria will result in claim denials.